Sanofi partners with BIG, EORTC, AFT to study amcenestrant for ER+ breast cancer treatment EP News Bureau Jun 4, 2021 Amcenestrant is an oral SERD that antagonises and degrades the estrogen receptor (ER), resulting in inhibition of the ER signaling…
